Company intelligence / Profile preview

Activus Pharma

Funabashi, Chiba, Japan

Ownership: Private
Development stage: Other

Overview

The APNT nanoparticle platform enabled Formosa Pharmaceuticals to advance ophthalmic drugs such as APP13007, which has FDA approval for post-surgical ocular pain and inflammation; additional programs remain in preclinical development

Therapeutic areas: Ophthalmology
Modalities: Small moleculeNanoparticle
Industry: Biotech

Partnerships

Partnerships occurred primarily via Formosa Pharmaceuticals following acquisition (Almac Discovery, Apotex, Saval Corporation, Cipla, Medvisis for APP13007 commercialization)

Beyond the preview

Go deeper on Activus Pharma.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Activus Pharma.

Explore the full profile